These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33194861)

  • 21. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.
    Zhou L; Ding Y; Gao Y; Yang B; Bao J; Ma J
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):1-9. PubMed ID: 31914334
    [No Abstract]   [Full Text] [Related]  

  • 23. A Case of Unexplained Warfarin Resistance: A Case Report and Literature Review.
    Favaedi M; Pasebani Y; Kabiri A; Rafati A; Jalali S; Kiani A; Ahmadi R; Shadmehr A; Amirmazloomi A; Khajali Z
    J Tehran Heart Cent; 2023 Oct; 18(4):302-306. PubMed ID: 38680643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic determinants of response to warfarin during initial anticoagulation.
    Schwarz UI; Ritchie MD; Bradford Y; Li C; Dudek SM; Frye-Anderson A; Kim RB; Roden DM; Stein CM
    N Engl J Med; 2008 Mar; 358(10):999-1008. PubMed ID: 18322281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.
    Kwon A; Jo SH; Im HJ; Jo YA; Park JY; Kang HJ; Kim HS; Cho HC; Lee YK
    J Thromb Thrombolysis; 2011 Nov; 32(4):467-73. PubMed ID: 21713378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.
    Kuanprasert S; Dettrairat S; Palacajornsuk P; Kunachiwa W; Phrommintikul A
    J Med Assoc Thai; 2009 Dec; 92(12):1597-601. PubMed ID: 20043560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up.
    Wypasek E; Mazur P; Bochenek M; Awsiuk M; Grudzien G; Plicner A; Undas A
    J Physiol Pharmacol; 2016 Jun; 67(3):385-93. PubMed ID: 27511999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
    Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
    Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study.
    Gemmati D; Burini F; Talarico A; Fabbri M; Bertocco C; Vigliano M; Moratelli S; Cuneo A; Serino ML; Avato FM; Tisato V; Gaudio RM
    PLoS One; 2016; 11(9):e0162084. PubMed ID: 27606428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
    Bedewy AML; Sheweita SA; Mostafa MH; Kandil LS
    Indian J Hematol Blood Transfus; 2018 Apr; 34(2):328-336. PubMed ID: 29622878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
    Molden E; Okkenhaug C; Ekker Solberg E
    Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
    Azzam H; Elwakeel H; Awad I; El-Farahaty R; El-Gilany AH; El-Sharawy S
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):121-6. PubMed ID: 24978953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement.
    Liu J; Guan H; Zhou L; Cui Y; Cao W; Wang L
    Am J Transl Res; 2019; 11(4):2507-2515. PubMed ID: 31105858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.